Cargando…

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallera, Daniel A., Kreitman, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466112/
https://www.ncbi.nlm.nih.gov/pubmed/30577664
http://dx.doi.org/10.3390/biomedicines7010001
_version_ 1783411034954924032
author Vallera, Daniel A.
Kreitman, Robert J.
author_facet Vallera, Daniel A.
Kreitman, Robert J.
author_sort Vallera, Daniel A.
collection PubMed
description Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.
format Online
Article
Text
id pubmed-6466112
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64661122019-04-19 Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity Vallera, Daniel A. Kreitman, Robert J. Biomedicines Review Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue. MDPI 2018-12-21 /pmc/articles/PMC6466112/ /pubmed/30577664 http://dx.doi.org/10.3390/biomedicines7010001 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vallera, Daniel A.
Kreitman, Robert J.
Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title_full Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title_fullStr Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title_full_unstemmed Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title_short Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
title_sort immunotoxins targeting b cell malignancy—progress and problems with immunogenicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466112/
https://www.ncbi.nlm.nih.gov/pubmed/30577664
http://dx.doi.org/10.3390/biomedicines7010001
work_keys_str_mv AT valleradaniela immunotoxinstargetingbcellmalignancyprogressandproblemswithimmunogenicity
AT kreitmanrobertj immunotoxinstargetingbcellmalignancyprogressandproblemswithimmunogenicity